证券代码：688114 证券简称：华大智造 公告编号：2024-076 董事会 深圳华大智造科技股份有限公司 2024 年 11 月 30 日 关于参加 2024 年度深圳辖区上市公司集体接待日活动的公告 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，深圳华大智造科技股份有限公司（以下 简称"公司"）将参加由深圳证监局和深圳证券交易所指导、深圳上市公司协会 与深圳市全景网络有限公司联合举办的"2024 年度深圳辖区上市公司集体接待 日"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2024 年 12 月 12 日（周四）14:30-17:00。届时公 司高管将在线就公司业绩、公司治理、发展战略、经营状况、股权激励和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 深圳华大智造 ...

证券代码：688114 证券简称：华大智造 公告编号：2024-075 深圳华大智造科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2024 年 12 月 9 日(星期一)下午 14:00-15:00 ● 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 ●投资者可于 2024 年 12 月 2 日(星期一)至 12 月 6 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 MGI_IR@mgi- tech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 深圳华大智造科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发布公司《2024 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2024 年第 ...

Core Viewpoint - 解码DNA has launched a single-cell solution for mouse pancreatic cancer tissue neutrophils, utilizing the DNBelab C-TaiM 4 platform, which enhances the efficiency of tissue dissociation and the quality of single-cell sequencing data [1] Group 1 - 解码DNA's new solution enables high-efficiency dissociation of pancreatic tissue samples [1] - The single-cell sequencing data produced is of high quality, facilitating advanced research in immunology [1] - The solution achieves a high capture rate of neutrophils within immune cells, benefiting researchers in the field [1]

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating a positive outlook for future performance [4][8]. Core Views - The company experienced a revenue decline of 15.19% year-on-year in the first three quarters of 2024, with total revenue reaching 1.869 billion yuan. The net profit attributable to the parent company was -463 million yuan [1][2]. - Despite short-term performance pressures due to macroeconomic conditions, geopolitical factors, and market competition, the company is expected to benefit from a recovery in domestic demand and expansion into overseas markets [2][4]. - The company continues to invest heavily in research and development, which is essential for its growth phase and product innovation [2][4]. Financial Summary - For Q3 2024, the company reported revenue of 660 million yuan, a decrease of 13.22% year-on-year and a 2.75% decline from the previous quarter. The net profit for this quarter was -165 million yuan [1][2]. - Cumulative sales of gene sequencers reached over 670 units, marking a 4% increase year-on-year, with significant growth in specific models such as DNBSEQ-G99 and DNBSEQ-E25 [3][4]. - The projected net profits for 2024, 2025, and 2026 are -565 million yuan, -232 million yuan, and 117 million yuan, respectively, indicating a gradual recovery [4][10]. Market Position and Strategy - The company is positioned as a leader in the domestic gene sequencing market, with expectations of increased market share due to the trend of domestic substitution and supportive government policies for equipment upgrades [4][10]. - The report highlights the potential for the gene sequencing industry to recover as the Federal Reserve begins to lower interest rates, which may stimulate demand [4]. Valuation - The target market capitalization for the company is estimated at approximately 27 billion yuan, with a target price of 65 yuan per share based on PS and DCF valuation methods [4][10].

公司点评 公 司 研 究 2024 年 11 月 11 日 买入/维持 华大智造(688114) 昨收盘:50.90 华大智造点评报告：销售装机量逆势微增，在手订单充足 ◼ 走势比较 (60%) (42%) (24%) (6%) 12% 30% 23/11/1324/1/2424/4/524/6/1624/8/2724/11/7 华大智造 沪深300 ◼ 股票数据 总股本/流通(亿股) 4.17/2.13 总市值/流通(亿元) 212.01/108.38 12 个月内最高/最低价 (元) 106.68/34.68 相关研究报告 <<华大智造点评报告：坚定研发投 入，基因测序仪业务持续扩大市场份 额>>--2024-05-20 <<华大智造点评报告：基因测序业务 快速打开海外市场，装机带动试剂收 入提升>>--2023-11-09 <<华大智造点评报告：自动化产品需 求萎缩影响短期收入，诉讼和解后全 球放量可期>>--2023-04-28 证券分析师：谭紫媚 电话：0755-83688830 E-MAIL：tanzm@tpyzq.com 分析师登记编号：S1190520090001 事件：近日，公司发布 202 ...

证券研究报告 | 公司点评 | 医疗器械 华大智造(688114) | --- | --- | |-----------------------------------------------------------|-------------------------| | | 报告日期:2024年11月09日 | | 海外拓展持续，耗材逐步放量 华大智造 2024 年三季报点评报告 | | 投资要点 公司披露 2024年三季报,2024年前三季度收入 18.7亿元,需求变动下收入同比 下滑 15.2%，归母净利润-4.6亿元; 其中 Q3 收入 6.6 亿元,同比下滑 13.2%， 归母净利润-1.7亿元。核心产品（基因测序板块）前三季度收入 15.4亿元,基因 测序仪累计销售获机量超 670台,同比增长 4%。我们认为,常态化需求以及宏 观环境等影响下全年增速或有压力,但随着新增装机量的提升以及海外拓展, 2025年核心板块收入增长可期, □ 年大智造:海外拓展持续,耗材逐步放量 ▲ Q3 收入承压,但部分区域已呈现复苏态势 2024 年前三季度基因测序仪业务实现收入 15.4 亿元，同比下降约 11%， ...

证券研究报告 | 季报点评 gszqdatemark 2024 11 08 年 月 日 华大智造（688114.SH） Q3 业绩短期承压，测序仪装机稳健增长，海外市场布局加速 华大智造发布 2024 年三季度报告。2024Q1-Q3，实现营业收入 18.69 亿 元，同比下滑 15.19%；归母净利润-4.63 亿元，同比下滑 134.28%；扣非后 归母净利润-4.97 亿元，同比下滑 104.56%。2024Q3，实现营业收入 6.60 亿 元，同比下滑 13.22%；归母净利润-1.65 亿元，同比下滑 65.54%；扣非后归 母净利润-1.73 亿元，同比下滑 60.82%。 观点：Q3 收入端下滑主要系宏观环境等多因素影响，利润端表现不及收入端 主要系毛利率波动及期间费用率抬升。测序仪装机稳健增长，以旧换新等利好 因素有望驱动需求释放。海外市场加速拓展，本土化经营持续推进，2025 年 有望迎来恢复性增长。 Q3 收入端下滑主要系宏观环境、竞争加剧等多因素影响，毛利率波动及期间 费用率抬升导致利润端表现不及收入端。2024Q3 收入端下滑主要系宏观环 境、地缘政治、竞争加剧等多因素影响，毛利率波动 ...

[Table_MainInfo] 公司研究/医药与健康护理/医疗保健设备与用品 证券研究报告 华大智造（688114）公司季报点评 2024 年 11 月 08 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-------------------------------------------------------|--------------| | 股票数据 | | | 11 [ Table_StockInfo 月 07 日收盘价（元） ] | 50.11 | | 52 周股价波动（元） | 34.68-106.68 | | 总股本 / 流通 A 股（百万股） | 417/213 | | 总市值 / 流通市值（百万元） | 20872/10670 | | 相关研究 | | | [Table_ReportInfo] 《基因测序仪中国新增装机市场份额 | 47.3% ， | | 蝉联第一》 2024.06.12 | | | 《基因测序板块持续高增，海外拓展加速》 | | | 2023.12.25 | | 市场表现 [Table_QuoteInfo] -57. ...

Financial Performance - In the first three quarters of 2024, the company's revenue from gene sequencing instruments reached 1.54 billion yuan, accounting for 84% of total revenue [3] - Revenue from consumables was 960 million yuan, representing 62% of the total revenue from gene sequencing instruments [3] - The company reported a net loss due to a 15% year-over-year decline in revenue, influenced by macroeconomic conditions and market competition [4][5] Product Performance - The DNBSEQ-E25 low-throughput sequencer saw a 564% year-over-year increase in installation volume in the first three quarters [3] - The DNBSEQ-T7 sequencer's reagent consumption continued to grow, generating 450 million yuan in revenue, a 19% increase year-over-year [3] - The DNBSEQ-G99 and DNBSEQ-E25 models had installation numbers of 210 and 93 units respectively in the first three quarters of 2024 [7] Market Segmentation - Revenue from IVD products was 360 million yuan, accounting for 23% of total revenue, while non-IVD products generated 1.18 billion yuan, making up 77% [3] - In terms of application areas, research applications contributed 37.80%, clinical applications 50.17%, and emerging fields 12.03% [3] Regional Performance - The Chinese market generated 1.05 billion yuan in revenue, representing 68% of total revenue, while the Asia-Pacific region saw a 48% decline in revenue to 150 million yuan [3][4] - The Americas region achieved 120 million yuan in revenue, an 8% share, with a 29% year-over-year increase [4] Order Backlog - As of September 30, 2024, the company had an order backlog of 820 million yuan, with domestic orders at 520 million yuan (63%) and overseas orders at 300 million yuan (37%) [4] Cash Flow and Cost Management - The company has faced negative cash flow due to reduced cash collection rates and increased fixed costs from marketing and infrastructure investments [5] - To improve cash flow, the company plans to enhance customer credit management and optimize sales pricing strategies [5] Future Outlook - The company anticipates growth in overseas markets in 2025, particularly in regions along the Belt and Road Initiative and BRICS countries [7] - New applications in reproductive health, rare disease diagnosis, and tumor early screening are expected to drive industry growth [6]

地缘政治等影响短期表现，看好测序新品出海以及国内市场回温 华大智造（688114.SH） 医疗器械 证券研究报告/公司点评报告 2024 年 11 月 02 日 | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------------------------- ...